Fuzuloparib maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer: a multicenter, randomized, double-blind, placebo-controlled, phase III trial

Olaparib Maintenance Monotherapy in Asian Patients with Platinum-Sensitive Relapsed Ovarian Cancer: Phase III Trial (L-MOCA)

“…In the NORA trial (Chinese patients with PSR, 2 prior lines, with/without g BRCA m), overall investigator-assessed mPFS was 18.3 months in the niraparib arm ( 12 ), and in an interim analysis of the phase III FZOCUS-2 trial, Chinese patients with PSR ovarian cancer (with/without g BRCA m) randomized to fuzuloparib achieved an mPFS of 12.9 months (Supplementary Table S1; ref. 15 ). Head-to-head studies are needed in order to draw direct comparisons between the efficacy of different PARPis overall, and in patient subpopulations.…”

“…In SOLO2, mPFS among patients with BRCA m randomized to olaparib was 19.1 months ( 9 ). Among patients in the g BRCA m subgroup of L-MOCA, mPFS was 21.4 months, while in the phase II and III fuzuloparib studies, mPFS in patients with g BRCA m randomized to fuzuloparib was 10.3 and 12.9 months, respectively ( 15, 20 ). mPFS in s BRCA m and BRCA wt subgroups of the current study (i.e., non-g BRCA m) were 16.1 and 11.0 months, respectively.…”

A comprehensive comparison of medication strategies for platinum-sensitive recurrent ovarian cancer: A Bayesian network meta-analysis

“…We identified 4,488 records from four databases and 126 additional online records from American Society of Clinical Oncology and European Society of Medical Oncology. After excluding the duplicates and non-pertinent studies, 84 studies were left for full-text review, and finally 26 trials ( Parmar et al, 2003 ; González-Martín et al, 2005 ; Pfisterer et al, 2006 ; Alberts et al, 2008 ; Bafaloukos et al, 2010 ; Monk et al, 2010 ; Pujade-Lauraine et al, 2010 ; Aghajanian et al, 2012 ; Ledermann et al, 2012 ; Cognetti et al, 2013 ; Oza et al, 2015 ; Ledermann et al, 2016 ; Mirza et al, 2016 ; Coleman et al, 2017a ; Coleman et al, 2017b ; Pujade-Lauraine et al, 2017 ; Fujiwara et al, 2019 ; Mirza et al, 2019 ; Colombo et al, 2020 ; Pfisterer et al, 2020 ; Harter et al, 2021 ; Li et al, 2021 ; Pignata et al, 2021 ; Shi et al, 2021 ; Wang et al, 2021 ; Wu et al, 2021 ), met our eligibility criteria ( Figure 1 ).…”

“…Network meta-analysis included all treatments for PFS, 12 treatments for OS ( Figure 3A ), nine treatments for ORR, and 13 treatments for AEs ( Figure 3B ). Data was extracted from trials ( Parmar et al, 2003 ; González-Martín et al, 2005 ; Pfisterer et al, 2006 ; Alberts et al, 2008 ; Bafaloukos et al, 2010 ; Monk et al, 2010 ; Pujade-Lauraine et al, 2010 ; Aghajanian et al, 2012 ; Ledermann et al, 2012 ; Cognetti et al, 2013 ; Oza et al, 2015 ; Ledermann et al, 2016 ; Mirza et al, 2016 ; Coleman et al, 2017a ; Coleman et al, 2017b ; Pujade-Lauraine et al, 2017 ; Fujiwara et al, 2019 ; Colombo et al, 2020 ; Pfisterer et al, 2020 ; Li et al, 2021 ; Pignata et al, 2021 ; Wang et al, 2021 ; Wu et al, 2021 ).…”

“…Four therapeutic strategies were available for all comparisons ( Figure 3C ). Data was extracted from trials ( Aghajanian et al, 2012 ; Ledermann et al, 2012 ; Oza et al, 2015 ; Ledermann et al, 2016 ; Mirza et al, 2016 ; Coleman et al, 2017a ; Coleman et al, 2017b ; Pujade-Lauraine et al, 2017 ; Li et al, 2021 ; Pignata et al, 2021 ; Wu et al, 2021 ).…”